<DOC>
	<DOCNO>NCT02122159</DOCNO>
	<brief_summary>Pathologic myopia major cause legal blindness worldwide . In myopic macular degeneration ( MMD ) , degeneration retinal pigment epithelial ( RPE ) layer , associate photoreceptors , result vision loss . There currently standard treatment MMD . Transplantation intact sheet RPE suspension isolate individual RPE cell well autologous translocation RPE cell attempt treatment AMD . Human photoreceptors comprise two cell types-rods cone . Both close relationship outermost retinal cell , retinal pigment epithelium ( RPE ) . The RPE locate choroid photoreceptors . The RPE maintain photoreceptor function recycle photopigment , deliver , metabolize store vitamin A , phagocytosing rod photoreceptor outer segment , transport iron small molecule retina choroid , maintain Bruch 's membrane absorb stray light allow good image resolution . In essence , RPE layer critical function health photoreceptors retina whole . Human PRE ( hRPE ) transplantation may viable option treatment degenerative disease retina . MA09-hRPE cell fully differentiate human RPE cell derive embryonic stem cell . Transplanted hRPE cell prepare Advanced Cell Technology study rodent model macular degenerative disease . The data suggest subretinal injection ACT 's hRPE cell product rescue , least delay , loss visual function two animal model retinal degenerative disease . The main purpose study evaluate safety tolerability MA09-hRPE cellular therapy patient Myopic Macular Degeneration ( MMD ) . Another objective evaluate potential efficacy endpoint use future study RPE cellular therapy .</brief_summary>
	<brief_title>Research With Retinal Cells Derived From Stem Cells Myopic Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Myopia</mesh_term>
	<criteria>Adult male female 40 year age . Patient sufficiently good health reasonably expect survival least four year treatment Axial myopia equal great 8 diopter and/or axial length equal great 28 mm Clinical finding consistent MMD evidence one area &gt; 250microns geographic atrophy ( define AgeRelated eye Disease Study [ AREDS ] study ) involve central fovea . GA define attenuation loss RPE observe biomicroscopy , OCT , FA . No evidence current prior choroidal neovascularization The visual acuity eye receive transplant well 20/80 . The visual acuity eye NOT receive transplant worse 20/400 . The eye advance disease bad vision study eye . Electrophysiological finding consistent maculainvolving geographic atrophy . Medically suitable undergo vitrectomy subretinal injection . Medically suitable general anesthesia wake sedation , need . Medically suitable transplantation embryonic stem cell line : Any laboratory value , fall slightly outside normal range , review Medical Monitor Investigators determine clinical significance . If determine clinically significant , patient may enrol study . Normal serum chemistry ( sequential multichannel analyzer 20 [ SMA20 ] ) hematology ( complete blood count [ CBC ] , prothrombin time [ PT ] , activate partial thromboplastin time [ aPTT ] ) screening test . ( NOTE : With exception abnormality specifically identify exclusion criterion ) Negative urine screen drug abuse . Negative human immunodeficiency virus ( HIV ) , hepatitis B ( HBV ) , hepatitis C ( HCV ) serology . No history malignancy ( exception successfully treat ( excise ) basal cell carcinoma [ skin cancer ] successfully treat squamous cell carcinoma skin ) . Negative cancer screen within previous 6 month : complete history &amp; physical examination ; dermatological screening exam malignant lesion ; negative fecal occult blood test &amp; negative colonoscopy within previous 7 year ; negative chest roentgenogram ( CXR ) ; normal CBC &amp; manual differential ; negative urinalysis ( U/A ) ; normal thyroid exam ; male , normal testicular examination ; digital rectal examination ( DRE ) prostate specific antigen ( PSA ) ; female , normal pelvic examination Papanicolaou smear ; If female , normal clinical breast exam , negative mammogram . If female childbearing potential , willing use two effective form birth control study . If male , willing use barrier spermicidal contraception study . Willing defer future blood , blood component tissue donation . Able understand willing sign inform consent . Presence active inactive CNV . Presence posterior staphyloma . Presence history retinal dystrophy , retinitis pigmentosa , chorioretinitis , central serious choroidopathy , diabetic retinopathy retinal vascular degenerative disease ( i.e . AMD ) MMD . History optic neuropathy . Macular atrophy due cause MMD . Presence glaucomatous optic neuropathy study eye , uncontrolled IOP , use two agent control IOP ( acetazolamide , beta blocker , alpha1agonist , antprostaglandins , carbonic anhydrase inhibitor ) . Cataract sufficient severity likely necessitate surgical extraction within 1 year . History retinal detachment repair study eye . History malignancy ( exception successfully treat [ excise ] basal cell carcinoma [ skin cancer ] successfully treat squamous cell carcinoma skin ) . History myocardial infarction previous 12 month . History cognitive impairment dementia may impact patient ability participate inform consent process appropriately complete evaluation . Any immunodeficiency . Any current immunosuppressive therapy intermittent low dose corticosteroid . Alanine transaminase/aspartate aminotransferase ( ALT/AST ) &gt; 1.5 time upper limit normal know liver disease . Renal insufficiency , define creatinine level &gt; 1.3 mg/dL . A hemoglobin concentration less 10gm/dL , platelet count le 100k/mm3 absolute neutrophil count le 1000/mm3 study entry . Serologic evidence infection Hepatitis B , Hepatitis C , HIV . Current participation clinical trial . Participation within previous 6 month clinical trial drug ocular systemic administration . Any sightthreatening ocular disease . Any history retinal vascular disease ( compromised bloodretinal barrier . Glaucoma . Uveitis intraocular inflammatory disease . Significant lens opacity medium opacity . Ocular lens removal within previous 3 month . Ocular surgery study eye previous 3 month If female , pregnancy lactation . Any medical condition , , Investigator 's judgment , interfere patient 's ability comply protocol , compromise patient safety , interfere interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>RPE cellular therapy</keyword>
	<keyword>MMD</keyword>
</DOC>